canada clinical guidance

Allergic rhinitis (hay fever): stepwise management

A Canadian clinical summary of allergic rhinitis (hay fever): stepwise management, with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Focused allergic rhinitis practice parameter for Canada. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:Canadian rhinitis parameter

Source-attributed clinical priorities

  • Confirm an allergic symptom pattern and relevant triggers while considering infection, medication, structural disease and asthma.
  • Use allergen avoidance where feasible, intranasal corticosteroid or other therapy matched to severity and preference, with technique reviewed.
  • Arrange allergy assessment when diagnosis is uncertain, symptoms remain uncontrolled or immunotherapy is being considered.
  • Persistent nasal obstruction, recurrent unilateral bleeding or loss of smell warrants assessment beyond allergy treatment.
sources for this section:Canadian rhinitis parameter

Practical assessment and management workflow

1
Identify seasonal or perennial triggers, eye symptoms, asthma, sleep and occupational exposure.
2
Examine nasal mucosa and consider testing only when it will change avoidance or immunotherapy.
3
Teach correct intranasal corticosteroid technique and combine non-sedating treatment according to severity.
4
Review adherence and response and refer uncertain, refractory or immunotherapy-eligible disease.
sources for this section:Canadian rhinitis parameter

Safety, red flags and urgent escalation

  • Escalate acute breathing compromise or systemic anaphylaxis rather than treating as rhinitis.
  • Avoid chronic topical decongestants because rebound congestion can develop.
  • Consider asthma control whenever allergic rhinitis and lower-airway symptoms coexist.
sources for this section:Canadian rhinitis parameter

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:Canadian rhinitis parameter

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Canadian rhinitis parameter

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Allergy, Asthma & Clinical ImmunologyFocused allergic rhinitis practice parameter for Canadaaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.